Trimetazidine in angina and poor muscle function: protocol for a randomized controlled study / 中华医学杂志(英文版)
Yu-Jie ZHANG; Jing-Xin WANG; Shi-Hui FU; Xiao-Ying LI.
Chinese Medical Journal
; (24): 1461-1466, 2019.
Artículo
en Inglés
| WPRIM | ID: wpr-799963
Background@#Low handgrip strength (HS) and declining gait speed (GS) are increasingly obvious with aging, requiring effective, and safe medication for treatment. Trimetazidine (TMZ) modified release tablets, a common anti-angina drug, has potential benefits for alleviating the condition, but this has not yet been fully studied and therefore is the aim of this study.@*Methods@#This is a prospective randomized controlled study. Fifty-eight eligible patients will be randomly assigned to one of two study groups TMZ group or control group. For the TMZ group, a dose of 35 mg of oral TMZ will be administered with a meal twice a day for 3 months, in addition to any conventional treatments for angina. Only conventional treatments for angina will be administrated in the control group. The primary outcome will be the 6-min walking distance and the secondary outcomes will be muscle strength (HS and pinch strength), GS, muscle endurance (five times sit-to-stand test), balance maintenance (tandem standing test), and the frequency of angina per week. Additionally, body mass index, circumferences (biceps, waist, hip, and calf), albumin levels, and the score on a five-question scale for sarcopenia will be obtained during the study.@*Discussion@#This study aims to evaluate the usefulness of TMZ in a population with poor muscle function. The results may provide an effective and safe medical treatment to people with low muscle strength or physical performance.@*Trial registration@#Chinese Clinical Trial Registry, ChiCTR1800015000; www.chictr.org.cn/showproj.aspx?proj=25445.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados